Mon, Oct 20, 2014, 7:23 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • droptrowbeastpiss droptrowbeastpiss Sep 7, 2013 7:42 PM Flag

    Glaxo Failure Good for ONCS - Partner ?

    ONCS' surge in volume and move higher Thursday was the direct result of Glaxo failing to meet endpoint results for their Phase 3 melanoma drug.

    As the competition falters and thins, ONCS could very well become a major player in this very lucrative market.

    Certainly Glaxo's now reevaluating their options and could very easily take a controlling interest in ONCS as they did with AGEN in this failed trial.

    Why this stock's not over $1 amazes me?

    Here's the story:

    LONDON—U.K. pharmaceutical company GlaxoSmithKline said Thursday that its experimental cancer vaccine MAGE-A3 has failed to achieve an important trial milestone, dealing a blow to one of the company's more promising drugs in development.

    The failure of a GlaxoSmithKline cancer vaccine in a clinical trial is a setback for a hot area of medicine that seeks to harness the body’s immune system to fight tumors. .

    Glaxo said the drug didn't meet one of its primary goals in a late-stage trial in patients with melanoma, but that trials will continue. The drug didn't significantly extend the disease-free life of patients compared with placebo.

    MAGE-A3 is an antigen-specific cancer immunotherapeutic, designed to train the immune system to recognize and eliminate cancer cells in a way that mitigates side effects.

    The drug is one of a slate of promising new pipeline medicines from Glaxo either undergoing trials or slated for regulatory decisions during this year. It is regarded as a potentially innovative medicine in the promising new field of cancer vaccines.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ONCS
0.465+0.025(+5.68%)Oct 20 3:58 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.